Generic name: inavolisib
Brand name: Itovebi
Dosage form: oral tablet (3 mg; 9 mg)
Drug class: PI3K inhibitors

Medically reviewed by Drugs.com on Jan 28, 2025. Written by Cerner Multum.

What is inavolisib?

Inavolisib is used in combination with other cancer treatments to treat adults with breast cancer that has spread to other parts of the body (metastatic) and has come back after treatment with medicines.

Your doctor will perform tests to make sure inavolisib is the right treatment for you.

Inavolisib may also be used for purposes not listed in this medication guide.

Inavolisib side effects

Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Inavolisib may cause serious side effects. Call your doctor at once if you have:

• high blood sugar--increased thirst, increased urination, dry mouth, fruity breath odor;

• nausea, vomiting;

• blurred vision;

• confusion;

• weight loss, increased appetite;

• severe diarrhea, blood in your stools, stomach pain; or

• blisters or ulcers in your mouth, red or swollen gums, trouble swallowing.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects of inavolisib may include:

• abnormal lab results;

• loss of appetite;

• rash;

• headache;

• feeling weak or tired;

• nausea; or

• new or worsening cough, fever, trouble breathing.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Related/similar drugs

Warnings

Use only as directed. Tell your doctor if you use other medicines or have other medical conditions or allergies.

Before taking this medicine

You should not take inavolisib if you are allergic to it.

Tell your doctor if you have or have ever had:

• diabetes or high blood sugar; or

• kidney disease.

You may need to have a negative pregnancy test before starting this treatment.

Both men and women using inavolisib should use effective birth control to prevent pregnancy. Inavolisib can harm an unborn baby if the mother or father is using this medicine.

Keep using birth control for at least 1 week after your last dose. Tell your doctor right away if a pregnancy occurs.

Inavolisib may affect fertility in men or women. Pregnancy may be less likely to occur while the mother or the father is using this medicine. Both men and women should still use birth control to prevent pregnancy because the medicine can harm an unborn baby.

Do not breastfeed while using this medicine, and for at least 1 week after your last dose.

How should I take inavolisib?

Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.

Inavolisib is usually taken once per day with or without food at the same time each day.

If you vomit shortly after taking inavolisib, do not take another dose. Take your next dose as scheduled.

You may be given other medications. Keep taking these medicines for as long as your doctor has prescribed.

Do not change your dose or stop using this medicine without your doctor's advice.

Your blood may need to be tested often.

Your blood sugar will also need to be checked before and during treatment.

Swallow the tablet whole and do not crush, chew, or break it.

Store at room temperature away from moisture and heat.

Inavolisib dosing information

Usual Adult Dose for Breast Cancer:

9 mg orally once a day, in combination with palbociclib and fulvestrant
Duration of therapy: Until disease progression or unacceptable toxicity

Comments:
-Ensure patients meet criteria for treatment based on PIK3CA cancer mutations.
-For pre- or perimenopausal women, administer a luteinizing hormone-releasing hormone (LHRH) agonist.
-Consider administering a LHRH agonist in men.
-Refer to the manufacturer product information for palbociclib and fulvestrant for complete dosing and administration recommendations.

Use: In combination with palbociclib and fulvestrant, for the treatment of endocrine-resistant, PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer following recurrence on or after completing adjuvant endocrine therapy

What happens if I miss a dose?

Use the medicine as soon as you can, but skip the missed dose if you are more than 9 hours late for the dose. Do not use two doses at one time.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking inavolisib?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What other drugs will affect inavolisib?

Other drugs may affect inavolisib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Copyright 1996-2025 Cerner Multum, Inc. Version: 1.01.